Your Oncology Trials: Ensure Regulatory Alignment & Faster Enrollment
Is Your Oncology Trial Caught Between the FDA and EMA?
Get the expert blueprint for navigating the transatlantic regulatory divide
and accelerating your trial timelines
For emerging biotechs, the divergent expectations of the FDA and EMA are the single greatest
threat to trial timelines and budgets. A strategy that satisfies one agency can lead to costly rework and delays with the other. This exclusive white paper, “Mastering the Regulatory Gauntlet,” moves beyond theory to provide a practical framework for success. It is designed specifically for Heads and Directors of Clinical Operations who are responsible for delivering results in this complex environment.
Inside, you will discover:
- A detailed breakdown of the FDA’s Project Optimus and the EMA’s preference for Overall Survival (OS), and what this means for your protocol design.
- How to leverage early engagement programs like OREEG and the PRIME scheme to de-risk your development plan.
- The operational blueprint for implementing ICH E6(R3) principles through a proactive, risk-based quality system like QualityDRIVE™.
- A structural solution to the “expertise gap” with the integrated Penta-Helix™ model, ensuring your trial is strategically sound from day one.
- A case study demonstrating how this integrated approach can save an estimated 18 months and over $50 million.
Unlock 25% Faster Enrollment
Get the end-to-end blueprint for moving beyond outdated feasibility
and building a high-performance network of oncology trial sites
Up to 85% of clinical trials fail to meet their enrollment timelines, and 11% of sites never enroll a single patient. For emerging bioteachs, this isn’t just a delay. It’s a direct threat to the viability of your asset. Relying on traditional, subjective site selection methods in today’s competitive landscape is a high-risk gamble. The white paper “From Selection to Success” provides a practical, data-driven framework for accelerating your trial. It is designed for Clinical Operations leaders who need to deliver faster enrollment without compromising quality.
Download this guide to learn:
- How to build a modern site selection matrix that moves beyond reputation to predict actual performance.
- The strategy for leveraging a global portfolio of sites to maximize patient diversity and recruitment speed.
- How Accelsiors’ AcceleROUTE™ methodology can cut study startup timelines by 20-30%.
- The role of the AI-powered WideSCOPE Intelligence™ platform in identifying high-performing sites that your competitors overlook.
- A case study detailing how this end-to-end approach delivered 25% faster enrollment in a competitive solid tumor trial.
